1. Mitsubishi Tanabe Pharma Corporation. [CANAGLU® 100 mg tablets. revised June 2019] https://medical.mt-pharma.co.jp/di/file/dc/can_a.pdf. Accessed 8 June 2021 (In Japanese).
2. Inagaki N, Harashima SI, Iijima H. Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients. Expert Opin Pharmacother. 2018;19(8):895–908. https://doi.org/10.1080/14656566.2018.1473378.
3. Inagaki N, Nangaku M, Sakata Y, et al. Safety and efficacy of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as monotherapy and in combination with antidiabetic agents in patients with type 2 diabetes mellitus – an interim analysis of post-marketing surveillance (SAPPHIRE). Jpn Pharmacol Ther. 2018;46(4):499–519 (In Japanese).
4. Inagaki N, Nangaku M, Sakata Y, et al. Safety and efficacy of canagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes mellitus – an interim analysis of post-marketing surveillance (SAPPHIRE). J New Remed Clin. 2019;68(1):9–37 (In Japanese).
5. Inagaki N, Nangaku M, Sakata Y, Sasaki K, Nakamura H, Hamada K. Safety and efficacy of canagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes mellitus – the interim analysis of post-marketing surveillance (SAPPHIRE), third report. J New Remed Clin. 2020;69(3):288–329 (In Japanese).